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Matched population-based study examining 35 
the risk of type 2 diabetes in people with and 36 
without diagnosed hepatitis C infection 37 
Abstract 38 
Meta-analyses have found hepatitis C virus (HCV) infection to be 39 
associated with an increased risk of type 2 diabetes mellitus (T2DM). 40 
Here, we examine this association within a large population-based study, 41 
according to RNA status.  42 
A data-linkage approach was used to examine the excess risk of 43 
diagnosed T2DM in people diagnosed with HCV-antibodies in Scotland 44 
(21,929 Ab+ves; involving 15,827 RNA+ves, 3927 RNA−ves and 2175 45 
with unknown RNA-status) compared to that of a three-fold larger 46 
general population sample matched for sex, age and postcode (65,074 47 
Ab−ves). To investigate effects of ascertainment bias the following 48 
periods were studied: up to one year before (pre-HCV)/within one year 49 
of (peri-HCV)/more than one year post (post-HCV) the date of 50 
HCV-diagnosis.  51 
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T2DM had been diagnosed in 2.9% of Ab+ves  (including 3.2% of 52 
RNA+ves and 2.3% of RNA-ves) and 2.7% of Ab−ves. A higher proportion 53 
of T2DM was diagnosed in the peri-HCV period (i.e. around the time of 54 
HCV-diagnosis) for the Ab+ves (22%) compared to Ab−ves (10%). In 55 
both the pre-HCV and post-HCV periods, only those Ab+ves living in 56 
less deprived areas (13% of the cohort) were found to have a significant 57 
excess risk of T2DM compared to Ab−ves (adjusted odds ratio in the 58 
pre-HCV period: 4.0 for females and 2.3 for males; adjusted hazard ratio 59 
in the post-HCV period: 1.5). These findings were similarly observed for 60 
both RNA+ves (chronic) and RNA−ves (resolved).  61 
In the largest study of T2DM among chronic HCV-infected individuals 62 
to date, there was no evidence to indicate that infection conveyed an 63 
appreciable excess risk of T2DM at the population level. 64 
 65 
Keywords: 66 
Hepatitis C, Type 2 Diabetes, Matched cohort study, Data linkage 67 
1 Introduction 68 
A large consistent body of evidence from several observational studies 69 
suggests that Hepatitis C virus (HCV) infection is associated with 70 
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insulin resistance (IR) and Type 2 diabetes mellitus (T2DM (1-4). In 71 
addition, several plausible pathways have been suggested to explain how 72 
HCV influences IR and T2DM) (5-7). However, estimates of the size of 73 
the effect of HCV on T2DM risk vary between different studies. Two 74 
different meta-analyses of a total of 47 different studies both showed 75 
approximately 70% increased odds/hazards of having diabetes for 76 
individuals with HCV infection compared to individuals without HCV 77 
infection (adjusted Odds Ratio (OR), 1.7; 95% Confidence Interval (CI), 78 
1.2-2.5 (3) ; and 1.7; 95% CI, 1.2-2.2 (8)). A recent population based 79 
cross sectional study from the US (9), however, found little evidence of 80 
increased risk to test diabetes positive in people with, compared to 81 
without, either current HCV-infection (OR, 1.1; 95% CI, 0.6-1.9) or 82 
with current or past HCV-infection (OR, 1.0; 95% CI, 0.6-1.7). In 83 
addition, a large population based cohort study from Southern Italy 84 
showed that compared to HCV−ve controls only people with HCV and 85 
elevated alanine aminotransferase (ALT) levels were at higher odds of 86 
developing T2DM (OR,1.5; 95% CI, 1.0-2.2), while those with HCV 87 
and normal baseline ALT levels were at lower odds (OR, 0.6; 95% CI, 88 
0.3-1.1) (10). Another study of people enrolled in a community-based 89 
cohort in the US showed that HCV infection increased the risk of 90 
developing diabetes (adjusted hazard ratio (HR), 11.6; 95%CI 1.4-96.6), 91 
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but only among those at high risk of diabetes (based on body mass index 92 
and age) (11). Finally, a recent meta analysis suggested, on the basis of 93 
limited evidence, that having diabetes can also be a risk factor for 94 
contracting HCV (12). 95 
The heterogeneity of findings from the different studies indicates 96 
that, at a population level, the effect of HCV on T2DM risk is 97 
comparably low and varies between different strata of the population. 98 
Therefore, studies to estimate the size of the effect of HCV on T2DM in 99 
the general population need to be sufficiently large to allow examination 100 
of different strata of the population and need careful control of 101 
confounding. Factors that increase the risk for diabetes and that might 102 
differ between those with HCV and those without HCV include low 103 
socioeconomic status (13,14), a history of heroin dependence (15) and 104 
methadone treatment (16), high alcohol consumption (17), smoking 105 
(18), increasing age (19), male sex (19), non white ethnicity (20) and 106 
higher body mass index (14). 107 
To study the relationship between HCV infection and T2DM at a 108 
population level, we compared the risk of T2DM diagnosis in all people 109 
who have been diagnosed HCV antibody+ve with the risk of T2DM 110 
diagnosis in a three-times larger cohort of controls matched for the 111 
major confounding factors of sex, neighbourhood and age. To ascertain 112 
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wether any difference in the risk of T2DM was related to the virus itself 113 
or to factors associated with HCV-infection, we compared the 114 
relationship between HCV infection and T2DM in all people who had 115 
tested (i) HCV antibody+ve, (ii) HCV antibody+ve and RNA+ve and (iii) 116 
HCV antibody +ve  and RNA −ve . To reduce the potential effect of 117 
ascertainment bias associated with being diagnosed for HCV infection, 118 
we studied three different periods of T2DM diagnosis: (i) a diabetes 119 
diagnosis at least 1 year prior to HCV diagnosis; (ii) within ±1 year of 120 
HCV diagnosis and; (iii) later than one year post HCV diagnosis.  121 
Patients and Methods 122 
Data sources for diagnosis of HCV and T2DM 123 
Scotland has comprehensive national disease databases of people 124 
diagnosed with HCV-antibodies and of people diagnosed with diabetes. 125 
The database of people diagnosed with HCV-antibodies held at Health 126 
Protection Scotland holds information on more than 30,000 people from 127 
all over Scotland who have tested HCV antibody+ve between 1985 and 128 
2011 (see (21) for a description of the database). The Scottish Care 129 
Information – Diabetes Collaboration (SCI-DC) manages a national 130 
register that holds information on individuals with diagnosed diabetes 131 
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(over 300,000) in Scotland and is estimated to have included over 99% 132 
of people with diagnosed diabetes since 2004. Individuals are included 133 
on SCI-DC if they have a Read code1 for diabetes assigned in primary 134 
care or if they are seen in a hospital diabetes clinic (for a description of 135 
the database, see (22)). 136 
HCV antibody+ve cohort 137 
For the period up to the end of 2011, 31,468 records of HCV antibody+ve138 
 people from all over Scotland were held in the HCV diagnoses database. 139 
From the database, information was extracted on forename initial, a 140 
soundex encrypted version of the surname (soundex is a phonetic 141 
algorithm for indexing names by sound, as pronounced in English), date 142 
of birth, sex, RNA test results at first diagnosis (positive, negative, 143 
unknown) and date of first HCV+ve antibody test (hereafter referred to as 144 
date of HCV diagnosis). 145 
To enable linkage of the partially anonymised data in the HCV 146 
database to other databases, 24,975 (79%) records from the HCV 147 
database were probabilistically linked to the database of the community 148 
health index (CHI), a unique identifier used in medical records (23). 149 
1 Read codes are the standard clinical terminology system used in 
General Practice in the United Kingdom. 
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After linkage, information from CHI was added to the HCV antibody+ve150 
 cohort including full personal identifiers, postcode sector of residence at 151 
the time of HCV diagnosis, an indicator for social deprivation of the area 152 
of residence (Scottish Index of Multiple Deprivation, SIMD) (24) and an 153 
indicator and date for migration from Scotland. We then excluded 107 154 
people younger than 16 and a total of 588 individuals with missing or 155 
unclear information on SIMD, sex and diagnosis date. After these 156 
exclusions, 24,280 individuals remained in the study population (see 157 
Figure 1 in the Appendix). 158 
HCV antibody−ve cohort 159 
For every person in the HCV antibody+ve cohort, up to three people were 160 
randomly sampled without replacement from the CHI database who 161 
were (i) born within one calendar year; (ii) of the same sex; (iii) alive at 162 
the time of diagnosis of the matched person on the HCV database; (iv) 163 
lived in the same postcode sector (but not in the same postcode) at the 164 
time of HCV diagnosis; and (v) were not included in the HCV 165 
antibody+ve cohort. Given the low prevalence of HCV in the Scottish 166 
population (25), less than 2% of the HCV antibody−ve cohort will likely 167 
have undiagnosed HCV-infection; thus, this misclassification will have 168 
negligible influence on the results. For 2118 people in the HCV 169 
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antibody+ve cohort, no matching individual could be identified in the 170 
CHI database; these people were excluded from the HCV antibody+ve 171 
cohort. As a result, 22,162 matched groups were available for analysis. 172 
People in the HCV antibody−ve cohort were assigned an index date 173 
which corresponded to the diagnosis date of their matched cohort 174 
member. 175 
Diabetes 176 
To identify diagnosed diabetes status in both cohorts (HCV antibody+ve 177 
and HCV antibody −ve ), data were deterministically linked to the 178 
SCI-DC database based on CHI number. After linkage, information 179 
from SCI-DC was added to the data including type of diabetes (T1DM, 180 
T2DM and other/unknown) and date of diabetes diagnosis. For 11 HCV 181 
antibody +ve  people, diabetes was diagnosed but date of diabetes 182 
diagnosis was not available; these individuals, together with their 31 183 
matched individuals from the HCV antibody−ve cohort, were removed 184 
from analysis. An additional three individuals from the HCV 185 
antibody−ve cohort with a diabetes diagnosis were removed as they had 186 
no date for their diagnosis. A further 219 HCV antibody+ve individuals 187 
were removed together with 652 matched individuals from the HCV 188 
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antibody−ve cohort because they had been diagnosed with a type of 189 
diabetes other than T2DM. Additionally, 451 people from the HCV 190 
antibody−ve cohort were excluded because they had been diagnosed with 191 
a type of diabetes other than T2DM. 192 
Morbidity and mortality 193 
To identify further censoring dates in both cohorts, data were then linked 194 
deterministically to mortality data from the General Registrars Office of 195 
Scotland (GRO, see (26) for a description of the database) and the date 196 
of death was added to the cohort data. Cohort members were 197 
additionally linked deterministically to hospital databases, to ascertain 198 
whether, prior to the HCV-diagnosis date, they had been in hospital for 199 
an alcohol-related admission (ICD9: 571.[0-3], 291.[0-9], 535.3, 425.5, 200 
357.5, 305.0, 303.9; ICD10: E24.4, E51.2, F10.[0-9], G31.2, G62.1, 201 
G72.1, I42.6, K29.2, K70.[0-9], K86.0, O35.4, P04.3, Q86.0, R78.0, 202 
T51.[0,1,9], X[4,6]5, Y15, Y57.3, Y90.[3-8], Y91, Z50.2, Z71.4, Z72.1) 203 
or for an obesity-related admission (ICD9: 278.[0-9]; ICD10: E66). 204 
Three members of the HCV antibody+ve cohort matched to two different 205 
death records and were subsequently removed from analysis, leaving 206 
21,929 for analysis (Fig. 1). 207 
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Information Governance 208 
Data linkages were approved by the NHS National Services Scotland 209 
Privacy Advisory Committee and use of the CHI database was approved 210 
by the CHI Advisory Group. All linkages were undertaken at 211 
Information Service Division, Scotland and all personal identifiable 212 
information removed from the outputs prior to release of data to the 213 
research team for analysis. 214 
Statistical analysis 215 
The probability of T2DM diagnosis for those in the HCV antibody+ve 216 
compared to the HCV antibody −ve  cohort was determined for the 217 
following three time periods: i) up-to one year before HCV diagnosis 218 
(pre-HCV); ii) from one year before HCV diagnosis to one year after 219 
HCV diagnosis (peri-HCV); and iii) from one year after HCV diagnosis 220 
to the earlier of either the end of follow-up (November 1st, 2011), death, 221 
migration out of Scotland or diagnosis of T2DM (post-HCV). 222 
Generalized linear mixed models (R, package lme4) were used for 223 
the analysis of the odds of T2DM diagnosis pre-HCV and peri-HCV. 224 
Mixed effects Cox models (R, package coxme) were used for the 225 
analysis of the hazard of T2DM diagnosis post-HCV. In all three 226 
regression models, the year of HCV diagnosis (grouped into prior to 227 
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2000 and later than 1999), sex, social deprivation (grouped into three 228 
groups using the original quintiles: 1-2=high, 3=medium and 4-5=low 229 
deprivation) and age at HCV diagnosis were included as explanatory 230 
variables. Fractional polynomials were used to model age at HCV 231 
diagnosis (R, package mfp). To adjust for correlation within matched 232 
groups, a random group effect was added to all three models. 233 
To study if the estimated effect of HCV-infection on the probability 234 
of T2DM diagnosis was modified by period of HCV diagnosis, sex, 235 
social deprivation or age at HCV diagnosis, interaction-terms between 236 
these variables and HCV were added to the full model. Likelihood ratio 237 
tests were used for testing the statistical significance of interaction terms 238 
and those interaction terms that were not statistically significant 239 
(P>0.05) were removed. For statistically significant interaction terms, a 240 
synergy index (S) was calculated to demonstrate the excess risk from 241 
exposure (to both exposures) when there is interaction relative to the risk 242 
from exposure (to both exposures) without interaction. Influential 243 
values, outliers and model fit were ascertained in the final models 244 
excluding random group effects (R, package boot). The assumption of 245 
proportionality of hazards in the survival analysis was tested using 246 
Schoenfeld residuals (R, package survival). 247 
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To study the effect of chronic and resolved HCV infection, all final 248 
models were re-run separately for those in the HCV antibody+ve cohort 249 
who were initially tested (i) RNA-positive (indicative of chronic HCV) 250 
and (ii) RNA-negative (indicative of resolved HCV). Here, the HCV 251 
antibody−ve cohorts were composed only of people who were matched 252 
to RNA-positive (for ( i)) and RNA-negative (for (ii)) individuals. 253 
Results 254 
Characteristics of the study population 255 
Table 1 shows the composition of the study population comprising 256 
21,929 people in the HCV antibody+ve cohort and 65,074 people in the 257 
matched HCV antibody−ve cohort. Reflecting the composition of the 258 
HCV antibody +ve  population in Scotland, people in the HCV 259 
antibody+ve cohort were predominantly male (68%), born between 1960 260 
and 1980 (68%), were diagnosed with HCV after the year 2000 (70%) 261 
and were living at the time of HCV diagnosis in areas of highest 262 
deprivation (75%). 72% of the people in the HCV antibody+ve cohort 263 
were HCV-RNA+ve, 18% were HCV-RNA−ve and in 10% the RNA 264 
status was unknown. More than 97% of people in the HCV antibody+ve 265 
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cohort could be matched to three HCV antibody−ve people from the CHI 266 
database, while for people born before 1950 fewer matches were 267 
identified. 268 
Median follow-up time from HCV-diagnosis to censoring or end of 269 
follow-up was 6.4 years in the HCV antibody+ve cohort and 6.6 years in 270 
the HCV antibody−ve cohort; median age at HCV diagnosis was 33 271 
years. During a total follow-up period of 151,020 person-years from 272 
HCV-diagnosis to censoring in the HCV antibody+ve  cohort, 4016 273 
people died (2.66 per 100 person-years). In the HCV antibody−ve cohort, 274 
the total follow-up period was 463,977 person-years with 2633 deaths 275 
recorded (0.57 per 100 person-years). The proportion of people who 276 
have had an alcohol-related hospitalization prior to HCV-diagnosis was 277 
considerably higher in the HCV antibody+ve cohort (22%) than in the 278 
HCV antibody−ve cohort (4.5%), while there was not much difference in 279 
the proportion of people who have had an obesity-related hospitalization 280 
(both 0.3%) prior to HCV-diagnosis. 281 
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Diagnosis of T2DM in the HCV antibody+ve cohort compared to the 282 
HCV antibody−ve cohort 283 
Of 21,929 people in the HCV antibody+ve cohort, 628 (2.86%) had been 284 
diagnosed with T2DM, of whom 187 (30%) had been diagnosed with 285 
T2DM more than a year before they had been diagnosed HCV-positive 286 
and 141 (22%) had been diagnosed with T2DM within one calender year 287 
of their HCV diagnosis (Table 2). This compares to 1772 out of 65,074 288 
(2.72%) in the HCV antibody−ve cohort who have been diagnosed with 289 
T2DM, of whom 524 (30%) had been diagnosed with T2DM more than 290 
a year before the matched person in the HCV antibody+ve cohort had 291 
been diagnosed HCV-positive and 184 (10%) had been diagnosed with 292 
T2DM within one calender year of their HCV diagnosis (Table 2). The 293 
difference between both cohorts in the proportion of people who were 294 
diagnosed with T2DM (0.14%) indicates an excess of 32 cases in HCV 295 
antibody+ve study population or 14 per 10,000 HCV-infected people, 296 
while for those who tested RNA+ve and RNA−ve, excess risks of 34 and 297 
20 per 10,000, respectively, were found. In both HCV antibody+ve and 298 
HCV antibody−ve cohorts the median age at diagnosis with T2DM was 299 
45 years. 300 
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Odds of T2DM diagnosis up to one year prior to HCV diagnosis 301 
In the HCV antibody−ve cohort, male sex and high social deprivation 302 
were associated with increased risks of having a diagnosis of T2DM in 303 
the period up to one year prior to HCV diagnosis. However, in the HCV 304 
antibody+ve cohort, the same variables were associated with decreased 305 
risk (Table 3). The 4345 women in the HCV antibody−ve cohort who 306 
resided in areas of lowest deprivation had the lowest risk of having a 307 
diagnosis of T2DM (0.4%), while the 941 women in the HCV 308 
antibody+ve cohort who resided in areas of lowest deprivation had the 309 
highest risk (2.4%; OR, 4.02; 95% CI, 2.29-7.04 P<0.01). The 28,267 310 
men in the HCV antibody−ve cohort who resided in areas of highest 311 
deprivation had a higher risk of having a diagnosis of T2DM (0.9%) than 312 
the 11,131 men in the HCV antibody+ve cohort who resided in areas with 313 
the same high deprivation (0.5%; OR, 0.61; 95% CI, 0.43-0.87 P<0.01). 314 
The synergy indices show negative interaction on an additive scale, 315 
indicating that the combined effects of male sex and HCV-infection and 316 
deprivation and HCV-infection were less than the sum of the effects of 317 
male sex and HCV-infection and deprivation and HCV-infection. 318 
Similar ORs were estimated when restricting the HCV-positive 319 
cohort to either only people who have tested RNA+ve (indicative of 320 
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chronic infection) or those who have tested RNA-negative (indicative of 321 
past infection; Table 3). 322 
Odds of T2DM diagnosis within ±one year of HCV diagnosis 323 
In the HCV antibody−ve cohort, male sex was associated with increased 324 
risks of having a diagnosis of T2DM in the period within one year of 325 
HCV diagnosis. However, in the HCV antibody+ve cohort, there was 326 
little difference between men and women (Table 4). The lowest risk of 327 
having a diagnosis of T2DM was observed for the 20,626 women in the 328 
HCV antibody−ve cohort (0.2%) while the highest risk was observed for 329 
the 6996 women in the HCV antibody+ve cohort (0.7%; OR, 3.78; 95% 330 
CI, 2.29-6.24 P<0.01). Increased risks of having a diagnosis of T2DM 331 
were also observed in the 14,746 men in the HCV antibody+ve cohort 332 
(0.6%) compared to men in the HCV antibody−ve cohort (0.3%), but 333 
because of the increased risk in males in the HCV antibody−ve cohort, 334 
the estimated adjusted OR was lower than in women (OR, 1.97; 95% CI, 335 
1.46-2.65; P<0.01). Again, the synergy index indicates negative 336 
interaction on an additive scale between the effect of male sex and 337 
HCV-infection (S=0.71). 338 
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The estimated increased odds for women in the HCV antibody+ve 339 
cohort compared to those in the HCV antibody −ve  cohort further 340 
increased when only women were included in the data set who had tested 341 
RNA-positive (OR, 4.57). Increased odds were also calculated for those 342 
women who tested RNA-negative (OR, 2.89). For men, estimates for the 343 
effect of HCV-infection on the odds of having a diagnosis of T2DM 344 
were similar in the full data set (OR, 1.97), the RNA-positives (OR, 345 
2.07) or RNA-negatives (OR, 2.02). However, restricting the cohort to 346 
RNA-negatives, the variance for estimates increased and some of the 347 
differences in the odds between people in the HCV-positive cohort and 348 
the HCV antibody−ve cohort were not statistically significant (Table 4). 349 
Hazard of T2DM diagnosis later than one year after HCV diagnosis 350 
In the HCV antibody −ve  cohort, increasing social deprivation was 351 
associated with an increased hazard of having a diagnosis of T2DM in 352 
the period later than one year after HCV diagnosis. However, in the 353 
HCV antibody+ve cohort, increasing social deprivation was associated 354 
with a decreased hazard of having a diagnosis of T2DM (Table 5). The 355 
lowest hazard of having a diagnosis of T2DM was observed for the 356 
14,298 people in the HCV antibody+ve cohort who lived in areas of 357 
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highest deprivation (1.4%) which was (non-significantly) lower than the 358 
hazard for the 34,470 members of the HCV antibody−ve cohort living in 359 
the same areas of high deprivation (1.9%; HR, 0.88; 95% CI, 0.75-1.03 360 
P=0.11). The highest hazard was observed for the 2401 people in the 361 
HCV antibody+ve cohort who lived in areas of lowest deprivation (2.5%) 362 
which was (significantly) higher than the hazard for the 10,957 members 363 
of the HCV antibody −ve  cohort living in the same areas of low 364 
deprivation (1.6%; HR, 1.53; 95% CI, 1.14-2.04 P<0.01). The synergy 365 
indices indicate negative interaction on an additive scale between the 366 
effect of deprivation and HCV-infection. 367 
Slightly higher effects of HCV-infection on the hazard of being 368 
diagnosed with T2DM more than one year after HCV diagnosis were 369 
estimated when restricting the HCV-positive cohort to those who have 370 
tested RNA+ve (indicative of chronic infection). Increased hazards were 371 
also estimated for those HCV antibody+ve who tested RNA-negative and 372 
who lived in areas with high or low deprivation; however, due to the 373 
small sample size, those differences were not statistically significant 374 




This study compares the risk of receiving a diagnosis of T2DM in a 377 
cohort of all people who have been diagnosed HCV antibody+ve in 378 
Scotland (the vast majority of whom will have acquired infection 379 
through injecting drug use) with that of a three times larger HCV 380 
antibody−ve cohort matched on year of birth, sex and neighbourhood. 381 
The HCV antibody+ve cohort was further stratified by RNA-status to 382 
check whether any additional risk attributed to HCV infection was 383 
related to the virus infection itself or to other factors related to the 384 
infection. Further the effect of HCV infection in three time periods - 385 
pre-HCV, peri-HCV and post-HCV diagnosis was studied to investigate 386 
any bias due to increased testing for T2DM at the time of HCV 387 
diagnosis. 388 
This study shows that nationwide over a time-period of 389 
approximately 12 years there were approximately 14 additional cases of 390 
T2DM for every 10,000 HCV-infected people compared to what would 391 
have been observed in a HCV antibody−ve cohort of identical size and 392 
characteristic. The excess risk was similarly low among RNA+ve when 393 
taking into account the excess risk among RNA−ve. Including those with 394 
HCV who are undiagnosed (nationwide approximately 50%, (25) ), we 395 
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would expect that the total excess number of people with HCV-antibody 396 
infection who have developed HCV-related T2DM up to this point in 397 
time is less than 100. 398 
While this is the first study to estimate the extra number of 399 
HCV-related T2DM cases for a whole nation, increases in risk of those 400 
with HCV have been reported elsewhere (1-4). For the national health 401 
system of Scotland, compared to total number of people reported to have 402 
been diagnosed with T2DM (265,000 between 2000 and 2012), the 403 
increase of less than 100 cases in a 12-year period is relatively small. 404 
Similarly, for the HCV-infected individual, compared to lifestyle 405 
choices related to an increase in T2DM risk, the increase in risk related 406 
to HCV-infection from 2.7% to 2.9% seems comparably low. The 407 
relatively small difference in risk observed in our study indicates the 408 
necessity to study the association between HCV-infection and T2DM in 409 
large, well-defined study populations. Ruhl et al. (9) found no 410 
association between HCV and either diabetes or insulin resistance (IR) 411 
in their US population based study, involving 277 HCV antibody+ve 412 
individuals (compared to the 21,929 studied here); a relationship 413 
between HCV and diabetes could only be found among those with 414 
elevated enzyme activity. Ruhl et al. thus suggest that the previously 415 
reported findings of a strong relationship with diabetes may have 416 
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resulted from the increased liver enzyme activity in the HCV 417 
populations studied (9). Further, a recent meta-analysis has found an 418 
association between the presence of IR and advanced fibrosis in those 419 
with HCV genotype 1 (the most common genotype in the US), but not 420 
for genotype 3 (27). We lacked data on liver enzyme activity, IR and 421 
HCV genotype in this database linkage study to be able to investigate 422 
this further in a larger cohort. 423 
Matching allowed us to control for the effects of age, sex and 424 
neighbourhood; the latter being a proxy for social deprivation and 425 
regional differences in testing and recording for both conditions. 426 
However, estimates of the number of additional cases of T2DM in those 427 
with HCV-infection could have been biased from other risk factors for 428 
T2DM for which information was not available. Ethnicity is known to be 429 
related to T2DM, with people of South Asian background living in the 430 
UK having 3-4 times higher risk of developing T2D during their life 431 
compared to the majority white population (20). Moreover, people of 432 
South Asian ethnicity are known to have a higher prevalence of HCV 433 
(28), so a higher proportion of people with South Asian ethnicity would 434 
be expected in the HCV-positive cohort. However, the South Asian 435 
population in Scotland is very small (≈1% in the 2001 census), so that 436 
confounding from a varying ethnic composition of the HCV-positive 437 
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cohort and the HCV-negative cohort can be expected to be small. 438 
Body-mass is a further known risk factor for T2DM, and it is possible 439 
that differences in BMI may confound the association between 440 
diagnoses of HCV and T2DM. However, since social deprivation and 441 
obesity are closely correlated in Scotland (14), matching by 442 
neighbourhood should have increased comparability of both cohorts, as 443 
indicated by similar proportions of people with a record of an obesity 444 
related hospitalization in the HCV antibody+ve and the HCV antibody445 −ve
 cohort. Similarly, alcohol consumption is a known risk factor for T2DM 446 
(29) and because alcohol consumption is positively related to 447 
HCV-status it could be expected that the proportion of people with high 448 
alcohol consumption was higher in the HCV-positive cohort compared 449 
to the HCV-negative cohort. Indeed, compared to people in the 450 
HCV-negative cohort, people in the HCV-positive cohort had a 451 
4.6-times higher risk of having an alcohol-related hospitalization. This 452 
bias from other risk factors related to T2DM might explain the 453 
observation in our study that compared to people in the HCV 454 
antibody −ve  cohort, people with resolved HCV-infection 455 
(RNA-negative) were still at higher risk of having a diagnosis of T2DM. 456 
The study also shows that the effect of diagnosed HCV-infection on 457 
the relative proportions of people with a diagnosis of T2DM was time 458 
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dependent. Partitioning of the risk period clearly showed that the 459 
increased risk is mainly due to increased T2DM diagnosis around the 460 
time of HCV diagnosis, while the 10% increased risk more than one year 461 
prior to HCV diagnosis and one year post HCV diagnosis were 462 
considerably lower than the estimate from the meta-analyses. 463 
Interestingly, the estimate of a 10% increased relative risk is very similar 464 
to that from the largest cohort study that had been included in the 465 
meta-analyses (30) although the estimate of absolute T2DM prevalence 466 
in the HCV antibody−ve cohort in our study (3.2%) was much lower than 467 
that in the US study (13%) or indeed any other cohort study but one 468 
included in the meta-analyses. Increased T2DM within ±1 year is likely 469 
related to ascertainment bias. However, neither guidelines by the 470 
Scottish Intercollegiate Guideline Network (SIGN guidelines 116) nor 471 
by the National Institute of Clinical Excellence recommend testing for 472 
HCV infection in people diagnosed with T2DM and guidelines by the 473 
European Association for the Study of the Liver only recommend testing 474 
for T2DM prior to treatment for HCV infection, since ‘poorly controlled 475 
diabetes’ is a contra-indication for treatment with interferon containing 476 
regimens. Therefore, the most likely reason for the increased T2DM 477 
diagnosis peri-HCV diagnosis is related to people showing clinical 478 
symptoms indicative of liver disease. It seems likely that for people with 479 
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signs of liver disease, a blood sample for glucose testing is collected at 480 
the same time as samples for HCV tests and liver function 481 
measurements. We do not have access to laboratory test databases in 482 
order to investigate the potential for ascertainment bias further. While 483 
there was a highly significant correlation between increasing age and the 484 
risk of T2DM diagnosis, there was no significant increase with age in the 485 
effect of HCV infection on the risk of T2DM (P=0.34 for inclusion of an 486 
HCV*age interaction term). This result indicates that the observed effect 487 
of HCV infection on the risk of T2DM is more likely caused by other 488 
factors related to HCV infection than by the (slowly progressing) action 489 
of the virus. However, our HCV infected cohort is still relatively young 490 
(median age at HCV diagnosis was 33 years) and has been followed up 491 
for a relatively short time (median of 6.4 years), thus the excess risk of 492 
T2DM may still change as our cohort advances in age and duration of 493 
infection. 494 
Male sex and living in areas of highest deprivation decreased effects 495 
of HCV infection on the risk of T2DM diagnosis. This effect 496 
modification was not related to follow-up time, age at HCV-infection or 497 
RNA-status since those did not differ within sex and social deprivation. 498 
Since male sex and high deprivation are positively related to T2DM risk, 499 
our observation does not confirm the suggestion from (11) that relative 500 
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effects of HCV on T2DM risk are higher in people at increased risk of 501 
T2DM. However, the effect modification could be explained by 502 
different uptake of health care (and thereby testing for diabetes) in men 503 
living in areas of high deprivation. The effect modification could explain 504 
some of the heterogeneity that both meta analyses found, since few of 505 
the reviewed studies stratified by sex and none by social deprivation. 506 
However, widely accepted biological models of the effects of HCV 507 
infection on T2DM risk (5-7) do not explain the observed effect 508 
modification. Moreover, while sex, social deprivation and year of birth 509 
were included in our matched analysis to increase efficiency of the study 510 
(31), the analysis of effect modification by sex, social deprivation, year 511 
and age was purely exploratory. 512 
Ideally, every person in the HCV-positive cohort should have been 513 
followed-up from the date of HCV-infection to development of T2DM 514 
or censoring. However, because date of HCV-infection was unknown, 515 
the follow-up period and thereby the risk of T2DM diagnosis pre-HCV 516 
diagnosis was heterogeneous. Additionally, the T2DM database is only 517 
approximately complete from 2004 onwards, with regional differences 518 
in the date from which diagnoses of T2DM were reported to the 519 
database. By matching people in the HCV antibody−ve cohort to those in 520 
the HCV antibody+ve cohort by year of birth and place of residence and 521 
 
Schnier 27 
by adequately controlling for the effect of matching in the analysis we 522 
managed to reduce the potential bias for the odds ratio from 523 
heterogeneous follow-up times. However, the estimated odds of T2DM 524 
diagnosis pre-HCV diagnosis in both cohorts are difficult to interpret. In 525 
addition, since date of HCV-infection and date of onset of T2DM both 526 
were unknown to us, the temporal relationship of onset of HCV infection 527 
and T2DM is not known. Indeed, T2DM has been described as a risk 528 
factor for contracting HCV (12). However, an estimated 86% of 529 
HCV-infection in Scotland is related to injecting drug use (32) and a 530 
large fraction of those diagnosed HCV-positive will have been infected 531 
in their early drug using career. Given that the risk of developing T2DM 532 
increases with age, it is unlikely that the increased risk for HCV in those 533 
with T2DM was responsible for the results of our study. 534 
Our study has demonstrated that on the population level the size of 535 
the effect of HCV antibody status on T2DM is smaller than effects of 536 
many life style choices (e.g., obesity, smoking and alcohol consumption) 537 
and therefore not as significant a public health concern as previously 538 
suggested from predominantly clinic based studies. Findings were 539 
similarly observed for both RNA+ves (chronic) and RNA−ves (resolved) 540 
which further indicates that the observed differences in risk of T2DM 541 
diagnosis were not related to the virus itself but to factors related to the 542 
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infection (e.g., factors related to drug abuse). However, given the 543 
increased risk for HCV-related disease progression in those affected by 544 
both conditions (33), further research is required to identify whether 545 
screening and earlier treatment for T2DM improves outcomes among 546 
people with a diagnosis of chronic HCV. Socio-economic status, sex and 547 
a history of alcohol use and injecting drug use modify the effect of HCV 548 
on T2DM which could explain some of the discrepancies between 549 
different studies given the different patterns of these factors in different 550 
populations. 551 
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Table 1: Characteristics of the study population 677 
 678 
 Variable Level HCV Ab+ve HCV Ab−ve % % 
Complete 
  cohort (N) cohort (N)  Matches1 
 Sex Women 7067 20,956 32 97 
 Men 14,862 44,118 68 97 
Year of birth <1950 1335 3859 6 90 
 1950-1959 2876 8521 13 96 
 1960-1969 7246 21,545 33 97 
 1970-1979 7616 22,656 35 98 
 ≥1980 2856 8493 13 97 
Year of diagnosis <2000 6592 19526 30 96 
 ≥2000 15,337 45,548 70 97 
Deprivation Low 2824 13,604 13/213 96 
 Medium 2678 9628 12/153 96 
 High 16,427 41,842 75/643 97 
Alcohol-related 
hospitalization2 
Yes 4812 2942 22/4.53  
Obesity-related 
hospitalization2 
Yes 60 209 0.3/0.33  
Total  21,929 65,074  97 
1 A complete match is 1 person in the HCV antibody+ve cohort and 3 people in the 
HCV antibody−ve cohort matched on year of birth, sex and postcode sector of 
residence. 
2 Alcohol and obesity related hospitalization prior to HCV diagnosis; ICD9 codes 
and ICD10 codes as listed in patients and methods. 
3 HCV antibody+ve and HCV antibody−ve, respectively. 
  679 
  680 
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Table 2: Number (and proportion) of people with T2DM in the HCV antibody+ve 681 
cohort (including for those PCR+ve and PCR-ve) and in the HCV antibody−ve cohort 682 








HCV Ab+ve & PCR+ve 
(N=15,827) 
HCV Ab+ve & 
PCR-ve (N=3,927) 
Diabetes+ve % Diabetes+ve % Diabetes+ve % Diabetes+ve % 
>1 year pre 524 0.81 187 0.85 157 0.99 23 0.59 
± 1 year 184 0.28 141 0.64 115 0.73 18 0.46 
>1 year post 1064 1.64 300 1.37 234 1.48 49 1.25 
Total 1772 2.72 628 2.86 506 3.20 90 2.29 
1 For those in the HCV antibody−ve cohort, HCV diagnosis data was taken to be the 684 
same as their respective HCV antibody+ve cohort members, for the purpose of analysis. 685 
 686 
 687 
  688 




Table 3: Odds of having been diagnosed with T2DM in the period up to 1 year before 691 
HCV diagnosis in the HCV antibody
EE
2 693 
+ve cohort (total and broken down by PCR status) 692 
compared to the HCV antibody−ve cohort1,
.   694 
 Sex Deprivation DiabetesA+ve DiabetesA+ve aOR
3 S4 
   /HCV Ab A−ve /HCV Ab A+ve (95% CI; P)  
AntibodyA+veE 
 F Low 17/4345 (0.4%) 23/941 (2.4%) 4.02 (2.32-6.96); P<0.01  
 F Medium 16/3036 (0.5%) 10/830 (1.2%) 1.92 (0.95-3.86); P=0.08 0.42 
 F High 101/13,575 (0.7%) 38/5296 (0.7%) 1.05 (0.66-1.69); P=1.00 0.32 
 M Low 77/9259 (0.8%) 40/1883 (2.1%) 2.33 (1.42-3.83); P<0.01 0.62 
 M Medium 57/6592 (0.9%) 19/1848 (1.0%) 1.11 (0.58-2.11); P=0.99 0.28 
 M High 256/28,267 (0.9%) 57/11,131 (0.5%) 0.61 (0.43-0.87); P<0.01 0.15 
AntibodyA+veEA and PCRA+veE 
 F Low 12/3067 (0.4%) 18/661 (2.7%) 4.35 (2.33-8.13); P<0.01  
 F Medium 10/2117 (0.5%) 7/575 (1.2%) 2.05 (0.93-4.50); P=0.09 0.42 
 F High 80/9098 (0.9%) 33/3576 (0.9%) 1.14 (0.67-1.93); P=0.96 0.35 
 M Low 59/6886 (0.9%) 34/1375 (2.5%) 2.61 (1.50-4.55); P<0.01 0.63 
 M Medium 44/4877 (0.9%) 16/1360 (1.2%) 1.23 (0.60-2.54); P=0.93 0.30 
 M High 202/20,936 (1.0%) 49/8280 (0.6%) 0.68 (0.46-1.01); P=0.06 0.19 
AntibodyA+veEA and PCRA−veE 
 F Low 0/841 (0.0%) 4/169 (2.4%) 6.14 (1.38-27.21); P<0.01  
 F Medium 4/669 (0.6%) 3/175 (1.7%) 2.69 (0.55-13.23); P=0.42 0.63 
 F High 18/3343 (0.5%) 4/1294 (0.3%) 0.74 (0.21-2.61); P=0.96 0.09 
 M Low 11/1339 (0.8%) 5/267 (1.9%) 2.45 (0.63-9.55); P=0.36 0.54 
 M Medium 9/1010 (0.9%) 3/283 (1.1%) 1.07 (0.25-4.66); P=1.00 0.32 
 M High 33/4450 (0.7%) 4/1739 (0.2%) 0.29 (0.09-0.98); P=0.04 0.01 
 
1For those in the HCV antibodyA−veEAcohort, HCV diagnosis date was taken to be the 695 
same as their respective HCV antibodyA+veEAcohort members, for the purpose of 696 
analysis. 697 
2Based on the likelihood-ratio test comparing the antibodyA+veEAcohort to the 698 
antibodyA−veEAcohort, interaction-terms other than sex × HCV and deprivation × 699 
HCV were deemed not statistically significant and therefore excluded from the 700 
final model. 701 
3Adjusted OR and P for exposure to HCV-infection within strata of sex and social 702 
deprivation. Odds ratios adjusted for age at HCV diagnosis, year of HCV 703 
diagnosis and the extra correlation due to the matching. 704 
4Synergy Index.  705 
  706 
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Table 4: Odds of having a diagnosis of T2DM in the period within ±1 year of the time 707 
of HCV diagnosis in the HCV antibodyA+veEA cohort (total and broken down by PCR 708 
status) compared to the HCV antibodyA−veEA cohort1,2EE  709 
 710 
 Sex DiabetesA+ve DiabetesA+ve aOR
3 S4 
  /HCV Ab A−ve /HCV Ab A+ve (95% CI; P)  
AntibodyA+veE 
 F 36/20,626 (0.2%) 46/6996 (0.7%) 3.78 (2.29-6.25); P<0.01  
 M 142/43,406 (0.3%) 95/14,746 (0.6%) 1.97 (1.46-2.65); P<0.01 0.71 
AntibodyA+veEA and PCRA+veE 
 F 25/13,230 (0.2%) 38/4486 (0.8%) 4.57 (2.56-8.18); P<0.01  
 M 111/30,223 (0.4%) 77/10,273 (0.7%) 2.07 (1.48-2.90); P<0.01 0.66 
AntibodyA+veEA and PCRA−veE 
 F 6/4591 (0.1%) 6/1555 (0.4%) 2.89 (0.52-16.01); P=0.31  
 M 18/6283 (0.3%) 12/2131 (0.6%) 2.02 (0.67-6.10); P=0.29 1.01 
1For those in the HCV antibodyA−veEAcohort, HCV diagnosis date was taken to be the 
same as their respective HCV antibodyA+veEAcohort members, for the purpose of 
analysis. 
2Based on the likelihood-ratio test comparing the antibodyA+veEAcohort to the 
antibodyA−veEAcohort, interaction-terms other than sex × HCV were deemed not 
statistically significant and therefore excluded from the final model. 
3Adjusted OR and P for exposure to HCV-infection within strata of sex. Odds ratios 
adjusted for age at HCV diagnosis, year of HCV diagnosis, social deprivation and 
the extra correlation due to the matching. 
4Synergy Index.  
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  713 
Table 5: Hazard of being diagnosed with T2DM in the period >1 year after the time of 714 
HCV diagnosis in the HCV antibodyA+veEA cohort (total and broken down by PCR status) 715 
compared to the HCV antibodyA−veEA cohort1,EE2 716 
 717 
 Deprivation DiabetesA+ve DiabetesA+ve aHR
3 S4 
  /HCV Ab A−ve /HCV Ab A+ve (95% CI; P)  
AntibodyA+veE 
 Low 175/10,957 (1.6%) 61/2401 (2.5%) 1.53 (1.14-2.04); P<0.01  
 Medium 137/7740 (1.8%) 43/2308 (1.9%) 1.14 (0.81-1.60); P=0.47 0.74 
 High 646/34,470 (1.9%) 196/14,298 (1.4%) 0.88 (0.75-1.03); P=0.11 0.36 
AntibodyA+veEA and PCRA+veE 
 Low 118/8158 (1.4%) 47/1750 (2.7%) 1.71 (1.21-2.40); P<0.01  
 Medium 100/5659 (1.8%) 35/1677 (2.1%) 1.26 (0.86-1.86); P=0.24 0.70 
 High 470/25,027 (1.9%) 152/10,448 (1.5%) 0.89 (0.74-1.07); P=0.22 0.39 
AntibodyA+veEA and PCRA−veE 
 Low 25/1459 (1.7%) 9/376 (2.4%) 1.46 (0.68-3.13); P=0.33  
 Medium 19/1395 (1.4%) 4/401 (1.0%) 0.70 (0.24-2.05); P=0.51 (-)5 
 High 91/6489 (1.4%) 36/2657 (1.4%) 1.10 (0.75-1.62); P=0.62 0.53 
1For those in the HCV antibodyA−veEAcohort, HCV diagnosis date was taken to be the 
same as their respective HCV antibodyA+veEAcohort members, for the purpose of 
analysis. 
2Based on the likelihood-ratio test comparing the antibodyA+veEAcohort to the 
antibodyA−veEAcohort, interaction-terms other than deprivation × HCV were deemed 
not statistically significant and therefore excluded from the final model. 
3Adjusted HR and P for exposure to HCV-infection within strata of social 
deprivation. Odds ratios adjusted for age at HCV diagnosis, sex, year of HCV 
diagnosis and the extra correlation due to the matching. 
4Synergy Index. 
5To ease comparison between different models, the reference category (antibodyA−ve
Aand low deprivation) was fixed between models. This caused a negative (invalid) 
synergy index.  
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Figure 1: Flowchart describing inclusion (boxes in the left column) and 720 




Eligible for selection of controls 
(n=24280) 
Linked to Diabetes database 
(n=22162) 






a) Younger than 16 at HCV diagnosis (n=107) 
b) Unknown on CHI (n=6493) 
c)  Missing variables (n=588) 
Excluded (n=2118): 
a) No matching control found (n=2118) 
Excluded (n=230): 
a) Diabetes other than T2DM (n=219) 
b) Missing / unclear date of diabetes diagnosis (n=11) 
Excluded (n=3): 
a) Linked to two different death records (n=3) 
